937247-91-1

Upstream product

• 5241-64-5 Boc-D-Trp-OH 
• 64-04-0 phenethylamine 

Downstream Products

• 937248-50-5 C₃₃H₃₇N₅O₂ 
• 937248-48-1 C₃₂H₃₅N₅O₂ 
• 937248-43-6 C₃₅H₃₈N₆O₂ 
• 1026987-13-2 C₃₇H₄₄N₆O₃ 
• 1027945-53-4 C₃₆H₄₂N₆O₃ 
• 1027012-43-6 C₄₀H₄₇N₇O₃ 
• 1025966-13-5 C₃₈H₄₃N₇O₃ 
• 1028286-70-5 C₃₉H₄₅N₇O₃ 
• 937248-46-9 C₃₆H₄₀N₆O₂ 
• 937248-45-8 C₃₄H₃₆N₆O₂ 

Relevant academic research and scientific papers

Substrate Fragmentation for the Design of M. tuberculosis CYP121 Inhibitors

The cyclo-dipeptide substrates of the essential M. tuberculosis (Mtb) enzyme CYP121 were deconstructed into their component fragments and screened against the enzyme. A number of hits were identified, one of which exhibited an unexpected inhibitor-like binding mode. The inhibitory pharmacophore was elucidated, and fragment binding affinity was rapidly improved by synthetic elaboration guided by the structures of CYP121 substrates. The resulting inhibitors have low micromolar affinity, good predicted physicochemical properties and selectivity for CYP121 over other Mtb P450s. Spectroscopic characterisation of the inhibitors′ binding mode provides insight into the effect of weak nitrogen-donor ligands on the P450 heme, an improved understanding of factors governing CYP121–ligand recognition and speculation into the biological role of the enzyme for Mtb.

Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1

A new series of growth hormone secretagogue (GHS) analogues based on the 1,2,4-triazole structure were synthesized and evaluated for their in vitro binding and their ability to stimulate intracellular calcium release to the cloned hGHS-1a ghrelin receptor expressed in LLC PK-1 cells. We have synthesized potent ligands of this receptor, some of them behaving as agonists, partial agonists, or antagonists. Some compounds among the most potent, i.e., agonist 29c (JMV2873), partial agonists including 21b (JMV2810), antagonists 19b (JMV2866) and 19c (JMV2844), were evaluated for their in vivo activity on food intake, after sc injection in rodents. Some compounds were found to stimulate food intake like hexarelin; some others were identified as potent hexarelin antagonists in this assay. Among the tested compounds, 21b was identified as an in vitro ghrelin receptor partial agonist, as well as a potent in vivo antagonist of hexarelin-stimulated food intake in rodents. Compound 21b was without effect on GH release from rat. However, in this series of compounds, it was not possible to find a clear correlation between in vitro and in vivo results.